Merck Serono SA
page
1
of
1
Pharma firm Merck slashes jobs in Switzerland
Apr 24, 2012 06:56 EDT
The struggling German pharmaceuticals group Merck KGaA said Tuesday it would close the headquarters of a subsidiary in Geneva, cutting 580 Swiss jobs and redeploying 750 others.
Could more IVF attempts really mean more success?
Feb 21, 2011 14:25 EST
NEW YORK (Reuters Health) - Researchers say couples trying to get pregnant through in vitro fertilization (IVF) could up their chances of success if they just keep trying.
Could more IVF attempts really mean more success?
Feb 21, 2011 14:24 EST
NEW YORK (Reuters Health) - Researchers say couples trying to get pregnant through in vitro fertilization (IVF) could up their chances of success if they just keep trying.
Correction: Horizon Pharma IPO filing
Aug 05, 2010 15:14 EDT
Correction: Horizon Pharma IPO filing. In a story Aug. 4 about Horizon Pharma Inc., The Associated Press reported erroneously on the company's partnerships on its drug Lodotra. Mundipharma holds the rights to Lodotra in Europe except for Germany and Austria, and Merck Serono has the rights to Lodotra in Germany and Austria.
Germany's Merck sees Q2 profit rise 69 percent
Jul 29, 2010 07:57 EDT
German drug and chemical maker Merck KGaA said Thursday that its second-quarter earnings were up 69 percent, led higher by healthy performances at its liquid crystals business and the Merck Serono pharmaceutical division.
Merck KGaA expects MS pill to lift drugs margin
Jun 30, 2010 07:07 EDT
FRANKFURT (Reuters) - German pharmaceuticals and chemicals company Merck KGaA is banking on an experimental multiple sclerosis (MS) pill to lift operating margins at its embattled drugs unit, it said on Wednesday.
Correction: Clinical Data earns story
Jun 15, 2010 14:58 EDT
Correction: Clinical Data earns story. In a story June 14 about Clinical Data Inc., The Associated Press erroneously reported the name of the company that formally filed for approval of the depression drug vilazodone. Clinical Data made the filing, not its partner Merck Serono.
Clinical Data gets app nod for depression drug
May 24, 2010 09:34 EDT
Clinical Data lands FDA application approval for depression treatment. Federal regulators have accepted an application for a depression drug marketed by Clinical Data Inc., the company said Monday.
Clinical Data gets app nod for depression drug
May 24, 2010 09:31 EDT
Clinical Data lands FDA application approval for depression treatment. Federal regulators have accepted an application for a depression drug marketed by Clinical Data Inc., the company said Monday.
Diabetes drug tied to reduced breast cancer risk
Apr 21, 2010 13:14 EDT
NEW YORK (Reuters Health) - Women who have used the diabetes drug metformin for more than five years may have a lower risk of breast cancer than diabetic women on other treatments, a new study finds.
Oncothyreon partner suspends cancer drug studies
Mar 23, 2010 13:44 EDT
Oncothyreon partner Merck Serono suspends studies of cancer drug Stimuvax over safety concerns. Clinical-stage biotechnology company Oncothyreon Inc. said Tuesday its partner Merck Serono temporarily suspended all clinical trials of the drug candidate Stimuvax because of potential safety issues.
Hope of new treatment for MS patients
Jan 21, 2010 07:46 EST
A newly-tested treatment for multiple sclerosis reduces relapse and deterioration in patients, without many of the negative side effects associated with other treatments, a study said.
New pill offers hope for multiple sclerosis patients
Jan 20, 2010 23:56 EST
A newly-tested treatment for multiple sclerosis reduces relapse and deterioration in patients, without many of the negative side effects associated with other treatments, a study said.
MS pills show promise and risk, studies say
Jan 20, 2010 17:08 EST
Mixed reviews for experimental pills to treat common form of multiple sclerosis. Tests of the first two oral drugs developed for treating multiple sclerosis show that both cut the frequency of relapses and may slow progression of the disease, but with side effects that could pose a tough decision for patients.
MS pills show promise and risk, studies say
Jan 20, 2010 17:02 EST
Tests of the first two oral drugs developed for treating multiple sclerosis show that both cut the frequency of relapses and may slow progression of the disease, but with side effects that could pose a tough decision for patients.
Germany's Merck will expand R&D in China
Nov 23, 2009 06:21 EST
German drugmaker Merck KGaA said Monday the company plans to invest euro150 million ($225 million) in a global research and development center in Beijing for its Serono drugs division.
Germany's Merck says Q3 net income falls 28 pct
Oct 26, 2009 07:18 EDT
German drug and chemical maker Merck KGaA saw net income fall 28 percent in the third quarter despite higher sales, as it spent more on product development and took a one-time charge related to its 2007 acquisition of Serono.
Merck says 3Q net income falls 28 percent
Oct 26, 2009 05:53 EDT
German drug maker Merck 3rd quarter net income falls 28 percent to $216 million. German drug and chemical maker Merck KGaA reported Monday that net income fell 28 percent to euro144 million ($216 million) in the third quarter as weak demand hurt revenue, but said its chemicals and liquid crystals divisions were recovering.
Fertility drug may reduce hot flashes: study
Sep 16, 2009 19:19 EDT
BOSTON (Reuters) - A drug that prevents premature ovulation during fertility treatments helped reduce the number of hot flashes by up to 80 percent in a small study of women entering menopause, researchers reported on Wednesday.
ZymoGenetics says RA drug misses advancement goals
Sep 10, 2009 18:33 EDT
ZymoGenetics says Atacicept did not meet goals for advancing directly to late-stage testing. ZymoGenetics Inc. said Thursday that its drug candidate Atacicept did not meet goals that would have automatically advanced it to late-stage clinical testing as a treatment for rheumatoid arthritis.
